Análisis de la acción Kiniksa Pharmaceuticals Ltd (KNSA)KNSAKiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Kiniksa Pharmaceuticals appears to be a good buy right now due to its recent strong financial performance, with Q2 revenue of $243.6 million representing a 55% year-over-year growth, and an upgraded full-year revenue guidance of $980 million to $995 million. The stock's current price of $78.08 is significantly below the average analyst price target of $98, suggesting a potential upside of 25.5%. However, a risk to consider is the high forward P/E ratio of 74.63, indicating that the stock may be overvalued if growth does not continue as expected.

4 analysts cover KNSA: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 53.50.